Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 20000 participants.
Also called NCT05874635
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 20,000 participants
- Sponsor
- Signos Inc
- Registry
-
NCT05874635
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05874635. Allocation not applicable; no masking; primary purpose treatment. Start 2023-05-11 (actual); primary completion 2028-05-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
- Condition
- Weight Loss
- Condition
- Metabolic Syndrome
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Central Obesity
- Condition
- Insulin Resistance
- Condition
- Glucose Intolerance
- Condition
- Metabolic Glucose Disorders
- Intervention (Device)
- Continuous Glucose Monitor Device
- Lead sponsor
- Signos Inc
Record details
- Record id
cardio:ct-nct05874635- Content hash
a47909d70f746e6fd37a819a1cef6835a705c17fba5947d7089f98cf0dbe4d06